Presista

2022: Stopping the sale of HIV and cancer drugs in the Russian Federation

At the end of September 2022, it became known about the termination by Johnson & Johnson of sales of several original drugs in Russia. We are talking about the following drugs: "Prezista" (for HIV therapy), "Velkade" (antitumor drug, bortezomib) and "Eprex" (stimulant of hematopoiesis).

The Ministry of Health canceled the state registration of these drugs Johnson & Johnson. Regulatory decisions regarding drugs are made on the basis of statements by the manufacturer or authorized legal entities.

Johnson & Johnson stopped selling Prezista drugs in Russia

By September 2022, analogues of all these drugs were registered in Russia, and J&J did not supply original drugs to Russia for several years.

The first Russian generic of "Presists" for HIV in 2014 was registered by "Pharmasintez." The drug is purchased centrally. In January-September 2022, the Federal Center for Planning and Organization of Drug Provision of Citizens PKU signed contracts for the supply of darunavir for 3.2 billion rubles. But J&J last brought the drug to Russia in 2018, according to RNC Pharma. That year, Prezistu accounted for 3.1% of darunavir sales in money and 2.6% in packages. By September 2022, generics of Prezista in Russia were registered with 11 enterprises.

Seven Russian companies have registered their drugs with bortezomib in the country, as well as Israeli Teva, Argentine Lab.Tuteur S.A.C.I.F.I.A, Indian Hetero and Dr. Reddy's. Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. The drug is purchased under the program "14 VND" and is included in the list of VEDs. In total, according to the Headway Company, state customers purchased bortezomib for 1.3 billion rubles in 2021. J&J last delivered Welkade to Russia in 2017, according to RNC Pharma.^[1]

Notes

Шаблон:Remarks